碳-14和氘标记β -位点淀粉样蛋白前体蛋白切割酶1抑制剂BI 1147560和BI 1181181的合成

IF 0.9 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Journal of labelled compounds & radiopharmaceuticals Pub Date : 2023-03-17 DOI:10.1002/jlcr.4022
Bachir Latli, Matt J. Hrapchak, Jonathan T. Reeves, Heewon Lee, Jinhua J. Song
{"title":"碳-14和氘标记β -位点淀粉样蛋白前体蛋白切割酶1抑制剂BI 1147560和BI 1181181的合成","authors":"Bachir Latli,&nbsp;Matt J. Hrapchak,&nbsp;Jonathan T. Reeves,&nbsp;Heewon Lee,&nbsp;Jinhua J. Song","doi":"10.1002/jlcr.4022","DOIUrl":null,"url":null,"abstract":"<p>The generation of amyloid beta peptides that aggregate in the brain is believed to play a major role in Alzheimer's disease. In theory, the inhibition of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1), which catalyzes the initial rate-limiting step in amyloid beta production, may slow or stop Alzheimer's disease. Herein, we report the preparation of two potent BACE1 inhibitors, <b>BI 1147560</b> (<b>1</b>) and <b>BI 1181181</b> (<b>2</b>), labeled with carbon-14 and with deuterium. The use of advanced key chiral intermediates like <b>3</b> and <b>5</b> shortened the carbon-14 syntheses of these two compounds to five and six steps, respectively, and helped in preparing them with very high chemical purity and enantiomeric excess without deviating from the process chemistry route. For the deuterium synthesis, oxetan-3-ylmethanamine <b>[</b><sup><b>2</b></sup><b>H</b><sub><b>6</b></sub><b>]-7</b> and 2-fluoro-2-methylpropan-1-amine <b>[</b><sup><b>2</b></sup><b>H</b><sub><b>6</b></sub><b>]-9</b> were prepared then used with the chiral intermediate <b>5</b> to furnish deuterium labeled <b>1</b> and <b>2</b>, respectively.</p>","PeriodicalId":16288,"journal":{"name":"Journal of labelled compounds & radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis of beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors BI 1147560 and BI 1181181 labeled with carbon-14 and deuterium\",\"authors\":\"Bachir Latli,&nbsp;Matt J. Hrapchak,&nbsp;Jonathan T. Reeves,&nbsp;Heewon Lee,&nbsp;Jinhua J. Song\",\"doi\":\"10.1002/jlcr.4022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The generation of amyloid beta peptides that aggregate in the brain is believed to play a major role in Alzheimer's disease. In theory, the inhibition of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1), which catalyzes the initial rate-limiting step in amyloid beta production, may slow or stop Alzheimer's disease. Herein, we report the preparation of two potent BACE1 inhibitors, <b>BI 1147560</b> (<b>1</b>) and <b>BI 1181181</b> (<b>2</b>), labeled with carbon-14 and with deuterium. The use of advanced key chiral intermediates like <b>3</b> and <b>5</b> shortened the carbon-14 syntheses of these two compounds to five and six steps, respectively, and helped in preparing them with very high chemical purity and enantiomeric excess without deviating from the process chemistry route. For the deuterium synthesis, oxetan-3-ylmethanamine <b>[</b><sup><b>2</b></sup><b>H</b><sub><b>6</b></sub><b>]-7</b> and 2-fluoro-2-methylpropan-1-amine <b>[</b><sup><b>2</b></sup><b>H</b><sub><b>6</b></sub><b>]-9</b> were prepared then used with the chiral intermediate <b>5</b> to furnish deuterium labeled <b>1</b> and <b>2</b>, respectively.</p>\",\"PeriodicalId\":16288,\"journal\":{\"name\":\"Journal of labelled compounds & radiopharmaceuticals\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of labelled compounds & radiopharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jlcr.4022\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of labelled compounds & radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jlcr.4022","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

摘要

在大脑中聚集的淀粉样肽的产生被认为在阿尔茨海默病中起着重要作用。理论上,抑制β位点淀粉样蛋白前体蛋白切割酶1 (BACE1)可能会减缓或阻止阿尔茨海默病。BACE1催化β淀粉样蛋白产生的初始限速步骤。在此,我们报道了两种有效的BACE1抑制剂BI 1147560(1)和BI 1181181(2)的制备,分别用碳-14和氘标记。使用先进的关键手性中间体,如3和5,将这两种化合物的碳-14合成分别缩短到5步和6步,并有助于在不偏离工艺化学路线的情况下制备具有非常高的化学纯度和过量的对映体。在氘的合成中,先制备了氧乙烷-3-甲基甲烷胺[2H6]-7和2-氟-2-甲基丙烷-1-胺[2H6]-9,然后与手性中间体5分别合成了标记为1和2的氘。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Synthesis of beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors BI 1147560 and BI 1181181 labeled with carbon-14 and deuterium

The generation of amyloid beta peptides that aggregate in the brain is believed to play a major role in Alzheimer's disease. In theory, the inhibition of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1), which catalyzes the initial rate-limiting step in amyloid beta production, may slow or stop Alzheimer's disease. Herein, we report the preparation of two potent BACE1 inhibitors, BI 1147560 (1) and BI 1181181 (2), labeled with carbon-14 and with deuterium. The use of advanced key chiral intermediates like 3 and 5 shortened the carbon-14 syntheses of these two compounds to five and six steps, respectively, and helped in preparing them with very high chemical purity and enantiomeric excess without deviating from the process chemistry route. For the deuterium synthesis, oxetan-3-ylmethanamine [2H6]-7 and 2-fluoro-2-methylpropan-1-amine [2H6]-9 were prepared then used with the chiral intermediate 5 to furnish deuterium labeled 1 and 2, respectively.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.30
自引率
0.00%
发文量
57
审稿时长
1 months
期刊介绍: The Journal of Labelled Compounds and Radiopharmaceuticals publishes all aspects of research dealing with labeled compound preparation and applications of these compounds. This includes tracer methods used in medical, pharmacological, biological, biochemical and chemical research in vitro and in vivo. The Journal of Labelled Compounds and Radiopharmaceuticals devotes particular attention to biomedical research, diagnostic and therapeutic applications of radiopharmaceuticals, covering all stages of development from basic metabolic research and technological development to preclinical and clinical studies based on physically and chemically well characterized molecular structures, coordination compounds and nano-particles.
期刊最新文献
Issue Information Preliminary Research of Radiolabeled Atezolizumab for the Noninvasive Evaluation of TNBC PD-L1 Expression In Vivo Issue Information Abstracts From the 29th International Isotope Society UK Meeting 17th November 2023 Lead-212/Bismuth-212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1